Abstract
Antitumor necrosis factor (TNF) therapy has been associated with adverse immunologic events including systemic lupus erythematosus. However, the development of polymyositis (PM)/dermatomyositis (DM) associated with anti-TNF therapy is extremely rare. We experienced a case of a 48-year-old female with rheumatoid arthritis (RA) who had anti-Jo-1 antibodies and interstitial lung disease but no previous history of PM/DM and who developed PM soon after the initiation of etanercept (ETN) therapy for RA. The patient recovered upon withdrawal from ETN and corticosteroid (CS) therapies. Only four reports of PM/DM associated with anti-TNF therapy for RA could be found in the literature. The patients described in three of the four reports were positive for anti-Jo-1 antibodies before the initiation of anti-TNF therapy, and in all the cases, recovery occurred after the cessation of anti-TNF-agent administration and CS therapy. These results suggest a relationship between the onset of PM/DM with anti-Jo-1 antibody and anti-TNF therapy for RA.
References
Weaver L (2004) Efficacy and safety of the anti-TNF biologic agents. Mod Rheumatol 14:101–112
Salomonsson S, Lundberg IE (2006) Cytokines in idiopathic inflammatory myopathies. Autoimmunity 39(3):177–190
Labioche I, Liozon E, Weschler B, Loustaud-Ratti V, Soria P, Vidal E (2004) Refractory polymyositis responding to infliximab: extended follow-up [letter]. Rheumatology (Oxford) 43:531–532
Selva-O’Callaghan A, Martinez-Costa X, Solans-Laque R, Mauri M, Capdevila JA, Vilardell-Tarres M (2004) Refractory adult dermatomyositis with pneumatosis cystoides intestinalis with infliximab [letter]. Rheumatology (Oxford) 43:1196–1197
Uthman I, El-Sayad J (2004) Refractory polymyositis responding to infliximab [letter]. Rheumatology (Oxford) 43:1198
Imperato AK, Smiles S, Abramson SB (2004) Long-term risks associated with biologic response modifiers used in rheumatic diseases. Curr Opin Rheumatol 16:199–205
Efthimiou P (2006) Tumor necrosis factor-alpha in inflammatory myopathies, pathophysiology and therapeutic implications. Semin Arthritis Rheum 36(3):168–172
Hengstman GJD, De Bleecker JL, Feist E, Vissing J, Denton CP, Manoussakis MN et al (2008) Open-label trial of anti-TNF-α in dermato- and polymyositis treated concomitantly with methotrexate. Eur Neurol 59:159–163
Iannone F, Scioscia C, Falappone PC, Covelli M, Lapadula G (2006) Use of etanercept in the treatment of dermatomyositis: a case series. J Rheumatol 33:1802–1804
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani CP, Einarsdottir H, Barbasso Helmers S et al (2008) A high incidence of disease flares in an open pilot study of infliximab in patients with refractory myopathies. Ann Rheum Dis 67:1670–1677
Harald AH, Bernard Z (2006) Evolution of dermatomyositis during therapy with a tumor necrosis factor α inhibitor. Arthritis & Rheum 55:982–984
Musial J, Undas A, Celinska-Lowenhoff M (2003) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Rheumatology (Oxford) 42:1566–1568
Urata Y, Wakai Y, Kowatari K (2006) Polymyositis associated with infliximab treatment for rheumatoid arthritis. Mod Rheumatol 16:410–411
Kiltz U, Fendler C, Braun J (2008) Neuromuscular involvement in rheumatic patients treated with anti-TNF therapy—three examples. J Rheum 35:2074–2075
Hirakata M (2000) Humoral aspects of polymyositis/dermatomyositis. Mod rheumatol 10:199–206
Disclosures
None.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ishikawa, Y., Yukawa, N., Ohmura, K. et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. Clin Rheumatol 29, 563–566 (2010). https://doi.org/10.1007/s10067-009-1370-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-009-1370-1